Calcipotriol/Betamethasone Sandoz 50 mikrog/ g / 0.5 mg/ g Noruega - noruec - Statens legemiddelverk

calcipotriol/betamethasone sandoz 50 mikrog/ g / 0.5 mg/ g

sandoz - københavn - kalsipotriolmonohydrat / betametasondipropionat - salve - 50 mikrog/ g / 0.5 mg/ g

Calcipotriol/Betamethasone Aristo 50 mikrog/ g / 0.5 mg/ g Noruega - noruec - Statens legemiddelverk

calcipotriol/betamethasone aristo 50 mikrog/ g / 0.5 mg/ g

aristo pharma gmbh - kalsipotriolmonohydrat / betametasondipropionat - gel - 50 mikrog/ g / 0.5 mg/ g

Calcipotriol/Betamethasone Orifarm 50 mikrog/ g / 0.5 mg/ g Noruega - noruec - Statens legemiddelverk

calcipotriol/betamethasone orifarm 50 mikrog/ g / 0.5 mg/ g

orifarm generics a/s - kalsipotriolmonohydrat / betametasondipropionat - gel - 50 mikrog/ g / 0.5 mg/ g

Advantan 0.1 % emulsiovoide Finlàndia - finès - Fimea (Suomen lääkevirasto)

advantan 0.1 % emulsiovoide

leo pharma a/s - methylprenisolone aceponate - emulsiovoide - 0.1 % - metyyliprednisoloniaseponaatti

Daivobet 50 / 500 mikrog/g voide Finlàndia - finès - Fimea (Suomen lääkevirasto)

daivobet 50 / 500 mikrog/g voide

leo pharma a/s - calcipotriol hydrate, betamethasone dipropionate - voide - 50 / 500 mikrog/g - kalsipotrioli

HYDRADERM 1 % emulsiovoide Finlàndia - finès - Fimea (Suomen lääkevirasto)

hydraderm 1 % emulsiovoide

evolan pharma ab - hydrocortisonum - emulsiovoide - 1 % - hydrokortisoni

Clobex 500 mikrog/ g Noruega - noruec - Statens legemiddelverk

clobex 500 mikrog/ g

galderma nordic ab - klobetasolpropionat - sjampo - 500 mikrog/ g

Fucidin-Hydrocortison 20 mg/ g / 10 mg/ g Noruega - noruec - Statens legemiddelverk

fucidin-hydrocortison 20 mg/ g / 10 mg/ g

leo pharma - fusidinsyrehemihydrat / hydrokortisonacetat - krem - 20 mg/ g / 10 mg/ g

Intrinsa Unió Europea - anglès - EMA (European Medicines Agency)

intrinsa

warner chilcott uk ltd. - testosterone - sexual dysfunctions, psychological - sex hormones and modulators of the genital system, - intrinsa is indicated for the treatment of hypoactive sexual desire disorder (hsdd) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.

Livensa Unió Europea - anglès - EMA (European Medicines Agency)

livensa

warner chilcott  deutschland gmbh - testosterone - sexual dysfunctions, psychological - sex hormones and modulators of the genital system, - livensa is indicated for the treatment of hypoactive sexual desire disorder (hsdd) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.